News

Since 2014, Horizon Europe and Horizon 2020 have invested more than €3.9 billion in nearly 1,900 health biotechnology research projects, strengthening Europe's capacity in stem cells, gene and cell therapies, vaccines, nanomedicines and more. 🖨️ Human bioprinting From 4D-printed surgical treatments to bio-printed corneas and alternatives to donor organs, Europe is also driving breakthroughs in tissue and organ bioprinting with €389+ million supporting 180 projects. These investments contribute directly to the EU's broader ambition to build a competitive, resilient and future-ready biotechnology ecosystem under the European Life Sciences Strategy. And this week's publication of the Commission's Biotech Act reinforces this ambition by creating clearer pathways for innovation, strengthening Europe's competitiveness, and supporting the scale-up of high-value biomanufacturing across the Union.